Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
8,942
datasets available to search
ShareScore release 0.9.0
Dataset results
8,942 results for “Prostate”
Heterogeneous activation of Wnt/β-catenin signaling in prostate cancer
GEO Series GSE141398. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Starving advanced prostate cancer cells by pharmacological gluose deprivation with a resveratrol trimer trans-Gnetin H [TGH]
GEO Series GSE240103. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
RNA Splicing of the BHC80 gene Facilitates Neuroendocrine Prostate Cancer Progression
GEO Series GSE86942. Homo sapiens. 9 samples. Type: Expression profiling by array.
Bulk RNA-seq analysis of prostate tissues treated with neoadjuvant ADT plus enzalutamide
GEO Series GSE183100. Homo sapiens. 73 samples. Type: Expression profiling by high throughput sequencing.
The effect of high fat diet on mouse prostate development
GEO Series GSE260450. Mus musculus. 4 samples. Type: Expression profiling by high throughput sequencing.
FASN inhibition in prostate cancer cells C4-2
GEO Series GSE224323. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Antagonistic interaction between androgen signaling and vitamin D signaling in prostate cancer
GEO Series GSE64657. Homo sapiens. 66 samples. Type: Genome binding/occupancy profiling by high throughput sequencing; Expression profiling by array.
A unique active role for HOTAIR to promote transcription in prostate cancer progression
GEO Series GSE221263. Homo sapiens. 35 samples. Type: Expression profiling by high throughput sequencing; Genome binding/occupancy profiling by high throughput sequencing; Other.
ESR1+ luminal epithelial cells contribute to androgen-independent prostate survival in the absence of SRD5A2
GEO Series GSE235514. Mus musculus. 3 samples. Type: Expression profiling by high throughput sequencing.
MiRNA Expression Profiling and Clinical Implications in Prostate Cancer Across Various Stages
GEO Series GSE290219. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Regulation of gene expression by AR agonism and AR antagonism in prostate cancer cells
GEO Series GSE279660. Homo sapiens. 29 samples. Type: Expression profiling by array.
NOTCH signaling is activated in and contributes to resistance in enzalutamide-resistant prostate cancer cells
GEO Series GSE123379. Homo sapiens. 12 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis."
<p>PURPOSE:</p> <p>For patients with oligometastatic/oligorecurrent/oligoprogressive lymph node metastases from PCa, metastases-directed therapy is an emerging strategy. The aim of this retrospective study was to evaluate the oncological outcome and pattern of recurrence in patients treated with stereotactic body radiation therapy (SBRT) to lymph node metastases.</p> <p>METHODS:</p> <p>In this multi-institutional analysis, patients with a maximum of five lymph node metastases from PCa treated with SBRT were included. Primary endpoints of the analysis were local control (LC), out-of-field nodal progression-free survival (NPFS), overall progression-free survival (PFS), and overall survival (OS).</p> <p>RESULTS:</p> <p>109 patients and 155 lymph node metastases were evaluated. Patients' median age was 70.8 years (range 51-84) and median PSA before SBRT was 1.88 ng/ml (range 0.3-45.5 ng/ml). The dose delivered to the target ranged from 25 to 48 Gy in 4-7 fractions; median BED<sub>1.5</sub> <sub>Gy</sub> was 198 Gy (range 108.3-432 Gy). With a median follow-up of 16 months, LC rates at 1 and 3 years were 93% and 86%, respectively. In-field progression of disease was observed in 11 (7%) lesions. One- and 3‑year NPFS was 59% and 29%, and median NPFS was 15 months. Rates of OS at 1 and 3 years were 100% and 95%. The median time to administration of a systemic treatment after SBRT was 7.8 months (1.7-54.8).</p> <p>CONCLUSION:</p> <p>SBRT is an effective and well-tolerated treatment option in the management of lymph node metastases from PCa. Prospective trials are necessary to better select patients who benefit most from this ablative focal treatment and better define the recurrence patterns.</p>
Dataset related to article "Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis."
<p>PURPOSE:</p> <p>The aim of the present study was to provide predictive factors for survival outcomes of oligometastatic prostate cancer (PC) patients treated with stereotactic body radiation therapy (SBRT) as a metastases-directed therapy (MDT).</p> <p>METHODS:</p> <p>In this cohort study, endpoints included overall survival (OS), progression-free survival (PFS), distant progression-free survival (DFS) and local control of treated metastases (LC). The binary classification tree approach with recursive partitioning analysis (RPA) was applied to stratify the patients into risk groups based on OS, PFS and DPFS; for each endpoint, disease-free interval (DFI) was calculated. We included patients with synchronous or metachronous metastases from prostate adenocarcinoma treated with SBRT.</p> <p>RESULTS:</p> <p>119 Metastases were treated with SBRT in 92 patients. Median follow-up was 22.2 months. Rates of OS at 1 and 3 years were 96.9% and 88.0%, while DPFS was 51.9% and 20.9%. Recursive partitioning analysis identified three prognostic classes for OS: Class 1: castration-sensitive patients (3 years OS 95%); Class 2: castration-resistant patients with low-intermediate risk NCCN disease (3 years OS 88.8%); Class 3: castration-resistant patients with high-risk NCCN disease (3 years OS 76.9%). Regarding DPFS, RPA divided patients into two classes, according to a cutoff value of DFI of 34 months (3 years PFS of 28.7% vs 5.8%). Three classes were identified for DPFS: Class 1: DFI < 34 months (3 years DPFS 9.1%); Class 2: DFI > 34 months and high-risk NCCN PC (3 years DPFS 21%); Class 3: DFI > 34 months and low-intermediate risk NCCN disease (3 years DPFS 60.2%).</p> <p>CONCLUSION:</p> <p>Oligometastatic PC represents nowadays a setting of particular interest in which local ablative therapies play a decisive role. In the present study, we recognized the importance of DFI, together with NCCN class risk, to predict the risk of new metastases after SBRT in oligometastatic PC.</p>
Dataset related to article "Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer."
<p>Tumor-associated macrophages (TAMs) represent a major component of the tumor microenvironment supporting tumorigenesis. TAMs re-education has been proposed as a strategy to promote tumor inhibition. However, whether this approach may work in prostate cancer is unknown. Here we find that Pten-null prostate tumors are strongly infiltrated by TAMs expressing C-X-C chemokine receptor type 2 (CXCR2), and activation of this receptor through CXCL2 polarizes macrophages toward an anti-inflammatory phenotype. Notably, pharmacological blockade of CXCR2 receptor by a selective antagonist promoted the re-education of TAMs toward a pro-inflammatory phenotype. Strikingly, CXCR2 knockout monocytes infused in Pten<sup>pc-/-</sup>; Trp53<sup>pc-/-</sup> mice differentiated in tumor necrosis factor alpha (TNF-α)-releasing pro-inflammatory macrophages, leading to senescence and tumor inhibition. Mechanistically, PTEN-deficient tumor cells are vulnerable to TNF-α-induced senescence, because of an increase of TNFR1. Our results identify TAMs as targets in prostate cancer and describe a therapeutic strategy based on CXCR2 blockade to harness anti-tumorigenic potential of macrophages against this disease.</p> <p> </p> <p>This dataset contain some prism documents, in order to help we attach a pdf information file about it</p>
Data set and results of regression analysis of gene variants in Prostate Cancer patients from Mexico-mestizo population.
<p>Genotyping assays were performed using TaqMan SNP Genotyping Assays probes C_27532228_20 and C_2362601_10 (Life Technologies, Carlsbad, CA, USA).</p> <p>Thermalcycler: StepOnePlus™ Real-Time PCR (Thermo Fisher Scientific, Waltham, MA, USA).</p> <p>Sample: genomic DNA from blood.</p> <p>Subjects: Prostate cancer patients and controls (healthy and benign prostatic hyperplasia). </p> <p>Results of Regression Anlysis for clinical features of gene SRD5A2 variants (rs9282858 and<strong> </strong>rs523349) in prostate cancer patients from Mexican-mestizo population.</p> <p>Starting with the full model, successive models are created, each one using one less regressor (or covariate) than the previous model. Each of the regressors currently in the model is removed to create a "trial" model excluding that regressor. The p-value of the current model (or full model) versus the trial model (or reduced model) is calculated, and the model with the smallest p-value is used as the next model. This method removes the least significant variable from the current model. If every p-value is smaller than the p-value cut off specified, the backward elimination method stops. The method also stops if all variables have been removed from the model, or if all variables left are included in the original reduced model. From the standpoint of further analysis, the final model becomes the "full model" for this set of potential regressors</p> <p>Ethics approval and consent to participate in the study: The protocol and informed consent were approved by the Ethics and Research Committee of the School of Medicine (Universidad Autonoma de Nuevo Leon), with registration number UR16-00007. In the data set, no data was included that compromises the confidentiality of the participating subjetcs.</p> <pre> </pre>
Dataset related to article "Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"
<p>This record contains raw data related to article “Linac-based stereotactic body radiation therapy for low and intermediate-risk prostate cancer : Long-term results and factors predictive for outcome and toxicity"</p> <p><strong>Introduction: </strong>Stereotactic body radiation therapy (SBRT) is considered an effective and safe treatment in patients with low- and intermediate-risk prostate cancer (PC). However, due to a lack of long-term follow-up and late toxicity data, this treatment is not universally accepted. The present study aimed to evaluate outcome and early and late toxicity in a cohort of patients with low- and intermediate-risk PC treated prospectively with linear accelerator (linac)-based SBRT.</p> <p><strong>Patients and methods: </strong>Patients with low- or intermediate-risk (NCCN criteria) PC were included. All patients received linac-based SBRT to 35 Gy in 5 fractions delivered on alternate days. Endpoints were toxicity, biochemical relapse-free survival (BRFS), metastatic progression-free survival (mPFS), and overall survival (OS).</p> <p><strong>Results: </strong>From 2012 to 2018, 178 patients were treated. Median baseline prostate-specific antigen (iPSA) was 6.37 ng/ml (range 1.78-20). Previous transurethral resection of the prostate (TURP) was present in 23 (12.9%) patients. Median follow-up was 58.9 months (range 9.7-89.9). BRFS rates at 1, 3, and 5 years were 98.3 (95% confidence interval, CI, 94.7-99.4%), 94.4 (95%CI 89.4-97), and 91.6% (95%CI 85.4-95.2), respectively. In univariate analysis, performance status (PS), iPSA, and nadir PSA (nPSA) were correlated with BRFS. In multivariable analysis iPSA and nPSA remained significant. BRFS rates at 5 years were 94.9% (95%CI 86.8-98) for International Society of Urological Pathology (ISUP) grade group 1, 93.2% (95%CI 80.5-97.7) for ISUP group 2, and 74.8% (95%CI 47.1-89.5) for ISUP group 3. At 1, 3, and 5 years, mPFS rates were 98.8 (95%CI 95.5-99.7), 96.2 (95%CI 91.9-98.3), and 92.9% (95%CI 87.2-96.2), respectively; OS rates were 100, 97.2 (95%CI 92.9-98.9), and 95.1% (95%CI 90-97.6), respectively. One (0.56%) case of grade 3 acute genitourinary (GU), one case of acute gastrointestinal (GI), and one case of grade 3 late GU toxicity were observed. GI toxicity positively correlated with prostate volume.</p> <p><strong>Conclusion: </strong>At long-term follow-up, linac-based SBRT continues to be a valid option for the management localized PC. Biochemical control remains high at 5 years, albeit with some concerns regarding the optimal schedule for unfavorable intermediate-risk PC. Considering the excellent prognosis, patient selection is crucial for prevention of severe late toxicity.</p>
Dataset related to article "Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice"
<p>This record contains data related to article "Morphometric vertebral fractures in patients with castration-resistant prostate cancer undergoing treatment with radium-223: a longitudinal study in the real-life clinical practice"</p> <p><strong>Abstract</strong></p> <p><strong>Purpose: </strong>Radium-223 was associated with high incidence of non-vertebral fractures in patients with castration-resistant prostate cancer (CRPC). However, it is still unclear whether radium-223 may induce skeletal fragility regardless of other therapies for CRPC. We aimed at evaluating the prevalence, incidence, and determinants of vertebral fractures (VFs), i.e., the most frequent complication of skeletal fragility, in CRCP patients undergoing radium-223 therapy in the real-life clinical practice.</p> <p><strong>Methods: </strong>We retrospectively reviewed 49 CRPC patients with symptomatic bone metastases treated with radium-223. Patients received median number of four radium-223 doses (range: 2-6) and were followed-up for a median period of 11 months (range: 6-44). VFs were assessed by a quantitative morphometry using lateral images of spine 11C-Choline PET/CT, excluding from the analysis the vertebral bodies affected by bone metastases.</p> <p><strong>Results: </strong>Before radium-223 administration, 24 patients (49%) had VFs significantly associated with duration of androgen deprivation therapy (ADT; odds ratio 1.29) and previous abiraterone therapy (odds ratio 3.80). During radium-223 therapy, incident VFs occurred in 25% of patients, in relationship with prevalent VFs (hazard ratio 6.89) and change in serum total alkaline phosphatase values (hazard ratio 0.97), whereas the correlations with ADT and abiraterone therapy were lost. Noteworthy, the risk of VFs did not correlate with the therapeutic end points of radium-223.</p> <p><strong>Conclusions: </strong>This study provides a first evidence that in real-life clinical practice, radium-223 therapy may induce skeletal fragility with high risk of VFs, likely by inhibition of bone formation and independently of ADT and abiraterone therapy.</p>
Dataset related to article "Post-biopsy cell-free DNA from blood: an open window on primary prostate cancer genetics and biology"
<p>This record contains data related to article "Post-biopsy cell-free DNA from blood: an open window on primary prostate cancer genetics and biology".</p> <p>Circulating cell-free DNA (ccfDNA), released from normal and cancerous cells, is a promising biomarker for cancer detection as in neoplastic patients it is enriched in tumor-derived DNA (ctDNA). ctDNA contains cancer-specific mutations and epigenetic modifications, which can have diagnostic/prognostic value. However, in primary tumors, and in particular in localized prostate cancer (PCa), the fraction of ctDNA is very low and conventional strategies to study ccfDNA are unsuccessful. Here we demonstrate that prostate biopsy, by causing multiple injuries to the organ, leads to a significant increase in plasma concentration of ccfDNA (P<0.0024) in primary PCa patients. By calculating the minor allele fraction at patient-specific somatic mutations pre- and post-biopsy, we show that ctDNA is significantly enriched (from 3.9 to 164 fold) after biopsy, representing a transient “molecular window” to access and analyze ctDNA. Moreover, we show that newly released ccfDNA contains a larger fraction of di-, tri- and multi-nucleosome associated DNA fragments. This feature could be exploited to further enrich prostate-derived ccfDNA and to analyze epigenetic markers. Our data represent a proof-of-concept that liquid tumor profiling from peripheral blood performed just after the biopsy procedure can open a “valuable molecular metastatic window” giving access to the tumor genetic asset, thus providing an opportunity for early cancer detection and individual genomic profiling in the view of PCa precision medicine.</p>
Multi-parmetric MRI prostate images
<p>Data used for the pipeline developed in https://github.com/I2Cvb/mp-mri-prostate</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.